Hepatitis C Drug ITMN-191 Appears Safe | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

1-in-4 People Have Fatty Liver Disease

Back to News Homepage
Next

Hepatitis C Protein May Help Fight HIV

Hepatitis C Drug ITMN-191 Appears Safe

The Editors at Hepatitis Central
April 4, 2008

Print this page

In addition to demonstrating a Hepatitis C anti-viral effect, an early trial investigating ITMN-191 met safety goals. With this good news, a Phase II study will evaluate this drug in combination with pegylated interferon and ribavirin.

InterMune Hepatitis C Drug Passes Study

© 2008 The Associated Press
April 1, 2008, 9:48AM
www.chron.com

BRISBANE, Calif. — Biotechnology company InterMune Inc. said Tuesday its hepatitis C drug candidate met safety goals in an early stage clinical trial and showed signs of effectiveness.

The drug candidate ITMN-191, being developed with Swiss drug company Roche, reduced hepatitis C RNA in the small-scale study, showing an antiviral effect. Early stage clinical trials typically measure a drug’s safety profile and whether it reaches its treatment target. The patient population is often too small to determine whether the drug candidate is actually effective.

The two companies plan a 14-day study on the drug in combination with two approved drugs, Pegasys and Copegus, also called ribavirin. An application was submitted to European regulatory authorities last month for the triple-combination study. Also, Roche has completed the tablet formulation of ITMN-191 and will use it in a midstage, or Phase II, clinical trial.

Shares of InterMune rose $2.84, or 19.1 percent, to $17.42. The stock has traded between $11.72 and $30.99 over the last 52 weeks.

No Comments - be the first!
Share
Share
Previous

1-in-4 People Have Fatty Liver Disease

Back to News Homepage
Next

Hepatitis C Protein May Help Fight HIV

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.